Discovery and Preclinical Characterization of NE-2-6 as a Potent Thyroid Peroxidase Inhibitor with Antithyroid Activity
Antioxidants · 04.08.2026 · 15 (8) · 967
DOI: 10.3390/antiox15080967 ↗Kurz gefasst
Fachartikel in der Zeitschrift Antioxidants, online erschienen am 04.08.2026. Verfasst von Min-Gyu Lee und 3 weiteren Autor:innen. Beteiligte Einrichtung: School of Life Sciences and Biotechnology, Korea University, Seoul 02841, Republic of Korea. Die Arbeit nennt 20 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: Korea University.
Abstract (Originalsprache)
Graves’ disease is an autoimmune hyperthyroid disorder in which thyroid peroxidase (TPO) plays a central role in excessive thyroid hormone production. However, current TPO-targeting drugs, such as propylthiouracil, have limited selectivity and can cause serious adverse effects. In this study, we established an integrated discovery pipeline to identify and optimize novel small-molecule TPO inhibitors. The pipeline began with high-throughput screening of approximately 7000 compounds from the KRICT chemical library for peroxidase inhibition, followed by cytotoxicity filtering and iterative medicinal chemistry to generate NE-2 derivatives. Lead compounds (NE-2-6, NE-2-7, and NE-2-8) were evaluated using enzymatic assays, selectivity profiling against myeloperoxidase (MPO) and lactoperoxidase (LPO), molecular docking, plasma pharmacokinetic profiling, and in vivo antithyroid pharmacodynamic testing in an Ad-TSHR289-induced thyroid hyperfunction model. NE-2-6 exhibited potent TPO inhibitory activity and relative selectivity within the tested peroxidase panel. UV–visible spectral scanning and H2O2-dependent inhibition assays suggested that NE-2-6 perturbs the heme-associated catalytic environment of TPO; however, these data do not establish a definitive binding mode or kinetic inhibition mechanism. In the Ad-TSHR289-induced thyroid hyperfunction model, NE-2-6 reduced serum T4 levels, supporting antithyroid pharmacodynamic activity. Because autoimmune endpoints and dose-matched PK–PD relationships were not fully assessed, the findings should be interpreted as preliminary preclinical evidence supporting further evaluation of NE-2-6 as a TPO-targeting antithyroid candidate.
Schlagwörter
Stichwörter der Autor:innen
Autor:innen und Institutionen
- School of Life Sciences and Biotechnology, Korea University, Seoul 02841, Republic of Korea.
- EsgelBio Co., Seoul 02841, Republic of Korea.
ORCID-Profile: Min-Gyu Lee
Förderung
- Korea University
Zitieren
APA
Lee, M. G., Kang, S., Kang, H. J., & Yun, C. W. (2026). Discovery and Preclinical Characterization of NE-2-6 as a Potent Thyroid Peroxidase Inhibitor with Antithyroid Activity. Antioxidants, 15(8), 967. https://doi.org/10.3390/antiox15080967
Vancouver
Lee MG, Kang S, Kang HJ, Yun CW. Discovery and Preclinical Characterization of NE-2-6 as a Potent Thyroid Peroxidase Inhibitor with Antithyroid Activity. Antioxidants. 2026;15(8):967. doi:10.3390/antiox15080967
BibTeX
@article{Lee2026,
author = {Lee, Min-Gyu and Kang, Suzie and Kang, Hyun-Jun and Yun, Cheol-Won},
title = {Discovery and Preclinical Characterization of NE-2-6 as a Potent Thyroid Peroxidase Inhibitor with Antithyroid Activity},
journal = {Antioxidants},
year = {2026},
volume = {15},
number = {8},
pages = {967},
doi = {10.3390/antiox15080967}
}
EUVIMED